BridgeBio Pharma, Inc. (BBIO) Stock
BBIO has an Alpha Score of 37 out of 100 (weak), computed on Nov 10, 2026 from 2 of 4 sub-scores. 1 member of Congress disclosed 8 trades in BBIO since 2025: 7 purchases and 1 sale, most recently Gilbert Cisneros (partial sale, Sep 29, 2026). 9 of the hedge funds AlphaScala tracks reported BBIO in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Viking Global Investors's at $741.02M. Company insiders reported 0 open-market buys and 10 sales on SEC Form 4 in the 90 days to Nov 9, 2026.
What is BBIO's Alpha Score?
How it works →Alpha Score of 37 reflects weak overall profile with moderate momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 10, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded BridgeBio Pharma, Inc. (BBIO)?
Most recent: Gilbert Cisneros (partial sale, Sep 29, 2026); records start Aug 8, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-09-29 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-05-11 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-04-29 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-19 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-18 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-03 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-09-22 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-08-08 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 6, 2026.
See all BBIO political trades →Which hedge funds own BBIO?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Viking Global Investors Andreas Halvorsen | 9.95M | $741.02M | -16% |
| Citadel Ken Griffin | 3.76M | $280.05M | +18% |
| D.E. Shaw David Shaw | 3.63M | $270.59M | +43% |
| Point72 Steve Cohen | 1.53M | $113.64M | NEW |
| Renaissance Technologies Jim Simons (founder) | 857K | $63.82M | +134% |
| Millennium Management Israel Englander | 488K | $36.32M | -23% |
| Bridgewater Associates Ray Dalio | 448K | $33.38M | +73% |
| Marshall Wace | 276K | $20.52M | -18% |
| Blackstone | 5K | $369.6K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are BridgeBio Pharma, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 30, 26 | Apuli Maricel | Chief Accounting Officer | SELL | 2.0K | $146K |
| Sep 17, 26 | Kumar Neil | Chief Executive Officer | SELL | 8.7K | $602K |
| Sep 17, 26 | Kumar Neil | Chief Executive Officer | SELL | 1.3K | $89K |
| Aug 19, 26 | Kumar Neil | Chief Executive Officer | SELL | 8.1K | $679K |
| Aug 19, 26 | Kumar Neil | Chief Executive Officer | SELL | 1.8K | $152K |
| Aug 19, 26 | Kumar Neil | Chief Executive Officer | SELL | 100 | $9K |
| Aug 18, 26 | Kumar Neil | Chief Executive Officer | SELL | 1.9K | $154K |
| Aug 18, 26 | Kumar Neil | Chief Executive Officer | SELL | 17.3K | $1.4M |
| Aug 18, 26 | Kumar Neil | Chief Executive Officer | SELL | 14.6K | $1.2M |
| Aug 18, 26 | Kumar Neil | Chief Executive Officer | SELL | 1.2K | $100K |
SEC Form 4 filings as of Nov 9, 2026
See cluster-buy signals across all tickers →What are BBIO's key statistics?
Key statistics as of Nov 10, 2026
How does BBIO's valuation compare with the Healthcare sector?
| Metric | BBIO | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -59.84% | 3.62% | 174 |
| Return on equity | -206.74% | 2.96% | 200 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
BBIO price chart
Powered by TradingViewWhat does BridgeBio Pharma, Inc. do?
BridgeBio Pharma is a biopharmaceutical company that discovers, develops, and delivers transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. The company operates through a distinctive decentralized hub-and-spoke model, where autonomous teams focus on individual disease conditions while a central hub provides shared clinical, regulatory, and commercial expertise. BridgeBio's commercial-stage pipeline includes Attruby (acoramidis), an oral small molecule transthyretin stabilizer for transthyretin-mediated amyloidosis cardiomyopathy, alongside late-stage programs for conditions including limb girdle muscular dystrophy, autosomal dominant hypocalcemia, achondroplasia, and Canavan disease. The company partners with leading academic institutions to advance early-stage research and accelerate the development of first-in-class treatments for underserved patient populations lacking adequate therapeutic options. BridgeBio's focused approach on genetic diseases with clear genetic drivers enables precision targeting at the disease source, positioning the company as a leader in precision medicine for rare genetic conditions.